SCD and central nervous system cancer: Targeting key lipid metabolism enzymes (SCD, FADS2, ACLY, and ACSL) to re-sensitize cancer cells to chemotherapy has already been demonstrated as a successful approach to combat glioma and glioblastoma [62–64].